Quick Answer
Beta Bionics, Inc. reported Operating Income Loss of -$71.68 million for the year ending 2025.
- Beta Bionics, Inc. showed a decrease of -58.4% in Operating Income Loss from 2024 to 2025.
- This data is from Beta Bionics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$9.45 million | Q2 2024: -$11.78 million | Q3 2024: -$10.98 million | Q1 2025: -$18.64 million | Q2 2025: -$19.87 million | Q3 2025: -$17.04 million.
- Over the full 3 years of available data (2023 to 2025), Beta Bionics, Inc.'s Operating Income Loss has declined by 99.9%.
- Historical annual values: Fiscal year 2025: -$71.68 million | Fiscal year 2024: -$45.25 million | Fiscal year 2023: -$35.85 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: